Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Pharmaust Limited ( (AU:NUZ) ).
Neurizon Therapeutics Limited has secured an Advance and Overseas Finding from AusIndustry for its NUZ-001 development, allowing overseas R&D expenditure for the 2025-2027 financial years to be eligible for a 43.5% cash rebate under the Australian Federal Government’s R&D Tax Incentive Program. This approval provides Neurizon with substantial non-dilutive funding, expected to result in a $5.6 million R&D Tax Rebate for FY2025, enhancing investor confidence and accelerating the development of NUZ-001, a promising treatment for ALS and other neurodegenerative diseases.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, particularly ALS, the most common form of motor neurone disease. The company is advancing its lead drug candidate, NUZ-001, and aims to accelerate access to effective ALS treatments while exploring broader neurodegenerative applications.
Average Trading Volume: 305,562
Technical Sentiment Signal: Sell
Current Market Cap: A$68.92M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.